HCA Healthcare (HCA)
(Delayed Data from NYSE)
$415.54 USD
+9.06 (2.23%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $415.66 +0.12 (0.03%) 7:56 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
HCA Healthcare (HCA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$405.87 | $475.00 | $360.00 | -0.15% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for HCA Healthcare comes to $405.87. The forecasts range from a low of $360.00 to a high of $475.00. The average price target represents a decline of 0.15% from the last closing price of $406.48.
Analyst Price Targets (23)
Broker Rating
HCA Healthcare currently has an average brokerage recommendation (ABR) of 1.42 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 1.43 a month ago based on 23 recommendations.
Of the 24 recommendations deriving the current ABR, 18 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 75% and 8.33% of all recommendations. A month ago, Strong Buy made up 73.91%, while Buy represented 8.7%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 18 | 18 | 17 | 16 | 16 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.42 | 1.42 | 1.43 | 1.45 | 1.45 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/17/2024 | Cowen & Co. | Ryan Langston | Strong Buy | Strong Buy |
10/10/2024 | KeyBanc Capital Markets | Matthew Gillmor | Not Available | Strong Buy |
10/1/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
9/30/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
9/27/2024 | Not Identified | Not Identified | Hold | Hold |
9/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/29/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
8/23/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
8/14/2024 | UBS | Aj Rice | Strong Buy | Strong Buy |
8/2/2024 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/30/2024 | Wells Fargo Securities | Stephen Baxter | Hold | Hold |
7/24/2024 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
7/24/2024 | Raymond James | John W Ransom | Moderate Buy | Moderate Buy |
7/24/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
7/24/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Strong Buy |
5/1/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
4/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/4/2024 | Goldman Sachs | Jamie Perse | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.42 |
ABR (Last week) | 1.42 |
# of Recs in ABR | 24 |
Average Target Price | $405.87 |
LT Growth Rate | 11.90% |
Industry | Medical - Hospital |
Industry Rank by ABR | 13 of 252 |
Current Quarter EPS Est: | 4.97 |
HCA FAQs
HCA Healthcare, Inc. (HCA) currently has an average brokerage recommendation (ABR) of 1.42 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms.
The average price target for HCA Healthcare, Inc. (HCA) is $405.87. The current on short-term price targets is based on 11 reports.
The forecasts for HCA Healthcare, Inc. (HCA) range from a low of $360 to a high of $475. The average price target represents a decline of $0.15 from the last closing price of $406.48.
The current DOWNSIDE for HCA Healthcare, Inc. (HCA) is 0.15%
Based on short-term price targets offered by 23 analysts, the average price target for HCA Healthcare comes to $405.87. The forecasts range from a low of $360.00 to a high of $475.00. The average price target represents a decline of 0.15% from the last closing price of $406.48.